CARE trial

The frequency of the primary end point was 10.2 percent in the pravastatin group and 13.2 percent in the placebo group, an absolute difference of 3 percentage points and a 24 percent reduction in risk (95 percent confidence interval, 9 to 36 percent; P = 0.003).

LDL cholesterol levels of 115 to 174 mg per deciliter (mean, 139) at baseline

There were no significant differences in overall mortality or mortality from noncardiovascular causes. Coronary bypass surgery was reduced by 26 percent (P=0.005), coronary angioplasty by 23 percent (P=0.01), and stroke by 31 percent (P=0.03).

There were no significant differences in overall mortality or mortality from noncardiovascular causes.

“The frequency of the primary end point was 10.2 percent in the pravastatin group and 13.2 percent in the placebo group, an absolute difference of 3 percentage points and a 24 percent reduction in risk (95 percent confidence interval, 9 to 36 percent; P = 0.003).”

Quoted from the abstract of N Engl J Med 1996, checked word for word against PubMed. PubMed 8801446 · Full paper (DOI)

• WOSCOPS (1995)In middle-aged men with moderate hypercholesterolemia and no prior MI, pravastatin significantly reduced coronary events and cardiovascular death without increasing noncardiovascular deaths.
• 4S (1994)In patients with coronary heart disease and elevated cholesterol, simvastatin reduced the risk of death and major coronary events compared with placebo over about 5.4 years.
• AFCAPS/TexCAPS (1998)In men and women with average cholesterol but low HDL-C and no known heart disease, lovastatin substantially lowered the risk of a first major coronary event.
• LIPID (1998)In patients with coronary heart disease and a broad range of cholesterol levels, pravastatin reduced death from coronary heart disease, overall mortality, and other cardiovascular events compared with placebo.